[home]
[thesaurus]
Click Here to return To Results
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
See this aricle in Pubmed
Article Abstract
Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab significantly slowed clinical progression at 76 weeks in those with low/medium tau and in the combined low/medium and high tau pathology population.
Related Tags
(click to filter results - removes previous filter)
adverse drug reaction
Alzheimer's disease
Alzheimer's disease,treatment of
amyloid
amyloid beta protein
amyloid plaques
donanemab
efficacy
monoclonal antibodies
safety
TRAILBLAZER-ALZ trial
treatment of neurologic disorder
Click Here to return To Results